Loading...
Market
Which executive role will Orbis Medicines fill from a major biotech by end of 2025?
2
Orbis Medicines•Danish•Novo Holdings•Sevan Habeshian•Christian Heinis•New Enterprise Associates•NEA•Eli Lilly•Cormorant•Forbion•Orbis•Morten Graugaard Døssing
Resolution / Starting Odds
CEO • 25%
CTO • 25%
CFO • 25%
None • 25%
Company press releases or industry news reports
Story
Danish Biotech Orbis Medicines Raises €90 Million for Oral Macrocycle Drugs Targeting Biologic Therapies
Jan 6, 2025, 04:14 PM
Orbis Medicines, a Danish biotechnology startup, has raised €90 million (approximately $93 million) in a Series A funding round to develop oral macrocycle drugs. The company, incubated by Novo Holdings and co-founded by Sevan Habeshian and Christian Heinis, aims to transform popular biologic therapies into oral medications using macrocyclic peptides, targeting validated blockbuster biologic targets. The funding round was led by New Enterprise Associates (NEA) and included investments from Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion. Orbis, which emerged from stealth with €26 million in seed funding last year, is now led by CEO Morten Graugaard Døssing, who previously served as executive chair of the company's board.
View original story
Similar markets
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Moderna • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Novartis • 25%
Roche • 25%
Pfizer • 25%
Focus on both equally • 25%
Focus on genetic engineering • 25%
Focus on cancer treatments • 25%
Focus on other areas • 25%
Yes • 50%
No • 50%
Merck • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
No change • 25%
CFO change • 25%
Both CEO and CFO change • 25%
CEO change • 25%
Neurological disorders • 25%
Other • 25%
Infectious diseases • 25%
Cancer • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Other • 25%
Novo Nordisk • 25%
Viking Therapeutics • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
GlaxoSmithKline • 25%